Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Science Translational Medicine

Volumn 10, Issue 436, 2018, Pages

  Tanyi, Janos L ^a   Bobisse, Sara ^b   Ophir, Eran ^b   Tuyaerts, Sandra ^b   Roberti, Annalisa ^a   Genolet, Raphael ^b   Baumgartner, Petra ^b   Stevenson, Brian J ^c   Iseli, Christian ^c   Dangaj, Denarda ^b   Czerniecki, Brian ^d   Semilietof, Aikaterini ^b   Racle, Julien ^b,c   Michel, Alexandra ^b   Xenarios, Ioannis ^c   Chiang, Cheryl ^a   Monos, Dimitri S ^e   Torigian, Drew A ^f   Nisenbaum, Harvey L ^f   Michielin, Olivier ^b,c   June, Carl H ^g   Levine, Bruce L ^g   Powel, Daniel J ^a   Gfeller, David ^b,c   Mick, Rosemarie ^g   Dafni, Urania ^h   Zoete, Vincent ^b,c   Harari, Alexandre ^b   Coukos, George ^a,b   Kandalaft, Lana E ^a,b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS OXIDIZED WHOLE TUMOR CELL LYSATE PULSED DENDRITIC CELL VACCINE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SOMATIC MUTATION; UNSPECIFIED SIDE EFFECT; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MUTATION; OVARY TUMOR; PROCEDURES;

ANTIGENS, NEOPLASM; BEVACIZUMAB; CANCER VACCINES; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; MUTATION; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85045325399     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aao5931     Document Type: Article

References (66)

1. A. Gadducci, S. Cosio, P. F. Conte, A. R. Genazzani, Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit. Rev. Oncol. Hematol. 55, 153-166 (2005).
2. M. Markman, P. Y. Liu, S. Wilczynski, B. Monk, L. J. Copeland, R. D. Alvarez, C. Jiang, D. Alberts; Southwest Oncology Group; Gynecologic Oncology Group, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A southwest oncology group and gynecologic oncology group trial. J. Clin. Oncol. 21, 2460-2465 (2003).
3. G. C. Stuart, First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol. Oncol. 90, S8-S15 (2003).
4. G. E. Peoples, B. W. Anderson, B. Fisk, A. P. Kudelka, J. T. Wharton, C. G. Ioannides, Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann. Surg. Oncol. 5, 743-750 (1998).
5. J. L. Murray, D. Przepiorka, C. G. Ioannides, Clinical trials of HER-2/neu-specific vaccines. Semin. Oncol. 27, 71-75 (2000).
6. K. Odunsi, A. A. Jungbluth, E. Stockert, F. Qian, S. Gnjatic, J. Tammela, M. Intengan, A. Beck, B. Keitz, D. Santiago, B. Williamson, M. J. Scanlan, G. Ritter, Y.-T. Chen, D. Driscoll, A. Sood, S. Lele, L. J. Old, NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63, 6076-6083 (2003).
7. R. H. Vonderheide, W. C. Hahn, J. L. Schultze, L. M. Nadler, The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679 (1999).
8. L. Zhang, J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, S. C. Rubin, G. Coukos, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
9. S. F. Adams, D. A. Levine, M. G. Cadungog, R. Hammond, A. Facciabene, N. Olvera, S. C. Rubin, J. Boyd, P. A. Gimotty, G. Coukos, Intraepithelial T cells and tumor proliferation: Impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 115, 2891-2902 (2009).
10. B. Clarke, A. V. Tinker, C.-H. Lee, S. Subramanian, M. van de Rijn, D. Turbin, S. Kalloger, G. Han, K. Ceballos, M. G. Cadungog, D. G. Huntsman, G. Coukos, C. B. Gilks, Intraepithelial T cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22, 393-402 (2009).
11. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 104, 3360-3365 (2007).
12. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 18538-18543 (2005).
13. C. A. Shah, K. H. Allison, R. L. Garcia, H. J. Gray, B. A. Goff, E. M. Swisher, Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol. Oncol. 109, 215-219 (2008).
14. M. Tomšová, B. Melichar, I. Sedláková, I. Šteiner, Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 108, 415-420 (2008).
15. M. Stumpf, A. Hasenburg, M.-O. Riener, U. Jütting, C. Wang, Y. Shen, M. Orlowska-Volk, P. Fisch, Z. Wang, G. Gitsch, M. Werner, S. Lassmann, Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: Relevance of clonal selection of T lymphocytes. Br. J. Cancer 101, 1513-1521 (2009).
16. K. Milne, M. Köbel, S. E. Kalloger, R. O. Barnes, D. Gao, C. B. Gilks, P. H. Watson, B. H. Nelson, Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLOS ONE 4, e6412 (2009).
17. R. G. W. Verhaak, P. Tamayo, J.-Y. Yang, D. Hubbard, H. Zhang, C. J. Creighton, S. Fereday, M. Lawrence, S. L. Carter, C. H. Mermel, A. D. Kostic, D. Etemadmoghadam, G. Saksena, K. Cibulskis, S. Duraisamy, K. Levanon, C. Sougnez, A. Tsherniak, S. Gomez, R. Onofrio, S. Gabriel, L. Chin, N. Zhang, P. T. Spellman, Y. Zhang, R. Akbani, K. A. Hoadley, A. Kahn, M. Köbel, D. Huntsman, R. A. Soslow, A. Defazio, M. J. Birrer, J. W. Gray, J. N. Weinstein, D. D. Bowtell, R. Drapkin, J. P. Mesirov, G. Getz, D. A. Levine, M. Meyerson; The Cancer Genome Atlas Research Network, Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517-525 (2013).
18. J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, T. Murayama, M. Kanai, Y. Mori, S. Matsumoto, S. Chikuma, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda, Y. Hosoe, S. Morita, M. Yokode, A. Shimizu, T. Honjo, I. Konishi, Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015-4022 (2015).
19. G. T. Motz, S. P. Santoro, L.-P. Wang, T. Garrabrant, R. R. Lastra, I. S. Hagemann, P. Lal, M. D. Feldman, F. Benencia, G. Coukos, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014).
20. E. A. Manning, J. G. M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, L. A. Emens, A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13, 3951-3959 (2007).
21. B. I. Rini, V. Weinberg, L. Fong, S. Conry, R. M. Hershberg, E. J. Small, Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107, 67-74 (2006).
22. Y. Huang, J. Yuan, E. Righi, W. S. Kamoun, M. Ancukiewicz, J. Nezivar, M. Santosuosso, J. D. Martin, M. R. Martin, F. Vianello, P. Leblanc, L. L. Munn, P. Huang, D. G. Duda, D. Fukumura, R. K. Jain, M. C. Poznansky, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109, 17561-17566 (2012).
23. R. K. Shrimali, Z. Yu, M. R. Theoret, D. Chinnasamy, N. P. Restifo, S. A. Rosenberg, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010).
24. T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen, W. Zou, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
25. D. S. Chen, I. Mellman, Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
26. Ö. Türeci, M. Vormehr, M. Diken, S. Kreiter, C. Huber, U. Sahin, Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin. Cancer Res. 22, 1885-1896 (2016).
27. U. Sahin, E. Derhovanessian, M. Miller, B.-P. Kloke, P. Simon, M. Lower, V. Bukur, A. D. Tadmor, U. Luxemburger, B. Schrörs, T. Omokoko, M. Vormehr, C. Albrecht, A. Paruzynski, A. N. Kuhn, J. Buck, S. Heesch, K. H. Schreeb, F. Müller, I. Ortseifer, I. Vogler, E. Godehardt, S. Attig, R. Rae, A. Breitkreuz, C. Tolliver, M. Suchan, G. Martic, A. Hohberger, P. Sorn, J. Diekmann, J. Ciesla, O. Waksmann, A.-K. Brück, M. Witt, M. Zillgen, A. Rothermel, B. Kasemann, D. Langer, S. Bolte, M. Diken, S. Kreiter, R. Nemecek, C. Gebhardt, S. Grabbe, C. Holler, J. Utikal, C. Huber, C. Loquai, Ö. Türeci, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222-226 (2017).
28. P. A. Ott, Z. Hu, D. B. Keskin, S. A. Shukla, J. Sun, D. J. Bozym, W. Zhang, A. Luoma, A. Giobbie-Hurder, L. Peter, C. Chen, O. Olive, T. A. Carter, S. Li, D. J. Lieb, T. Eisenhaure, E. Gjini, J. Stevens, W. J. Lane, I. Javeri, K. Nellaiappan, A. M. Salazar, H. Daley, M. Seaman, E. I. Buchbinder, C. H. Yoon, M. Harden, N. Lennon, S. Gabriel, S. J. Rodig, D. H. Barouch, J. C. Aster, G. Getz, K. Wucherpfennig, D. Neuberg, J. Ritz, E. S. Lander, E. F. Fritsch, N. Hacohen, C. J. Wu, An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217-221 (2017).
29. P. Romero, J. Banchereau, N. Bhardwaj, M. Cockett, M. L. Disis, G. Dranoff, E. Gilboa, S. A. Hammond, R. Hershberg, A. J. Korman, P. Kvistborg, C. Melief, I. Mellman, A. K. Palucka, I. Redchenko, H. Robins, F. Sallusto, T. Schenkelberg, S. Schoenberger, J. Sosman, Ö. Türeci, B. Van den Eynde, W. Koff, G. Coukos, The human vaccines project: A roadmap for cancer vaccine development. Sci. Transl. Med. 8, 334ps9 (2016).
30. J. Duraiswamy, K. M. Kaluza, G. J. Freeman, G. Coukos, Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73, 3591-3603 (2013).
31. P. Hatfield, A. E. Merrick, E. West, D. O'Donnell, P. Selby, R. Vile, A. A. Melcher, Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J. Immunother. 31, 620-632 (2008).
32. D.-Y. Cho, W.-K. Yang, H.-C. Lee, D.-M. Hsu, H.-L. Lin, S.-Z. Lin, C.-C. Chen, H.-J. Harn, C.-L. Liu, W.-Y. Lee, L.-H. Ho, Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: A phase II clinical trial. World Neurosurg. 77, 736-744 (2012).
33. D. Reyes, L. Salazar, E. Espinoza, C. Pereda, E. Castellón, R. Valdevenito, C. Huidobro, M. Inés Becker, A. Lladser, M. N. López, F. Salazar-Onfray, Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br. J. Cancer 109, 1488-1497 (2013).
34. E. M. von Euw, M. M. Barrio, D. Furman, E. M. Levy, M. Bianchini, I. Peguillet, O. Lantz, A. Vellice, A. Kohan, M. Chacón, C. Yee, R. Wainstok, J. Mordoh, A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. J. Transl. Med. 6, 6 (2008).
35. R. Zappasodi, S. M. Pupa, G. C. Ghedini, I. Bongarzone, M. Magni, A. D. Cabras, M. P. Colombo, C. Carlo-Stella, A. M. Gianni, M. Di Nicola, Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res. 70, 9062-9072 (2010).
36. F. S. Hodi, M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. MacRae, M. Nelson, C. Canning, I. Lowy, A. Korman, D. Lautz, S. Russell, M. T. Jaklitsch, N. Ramaiya, T. C. Chen, D. Neuberg, J. P. Allison, M. C. Mihm, G. Dranoff, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A. 105, 3005-3010 (2008).
37. C. L.-L. Chiang, L. E. Kandalaft, J. Tanyi, A. R. Hagemann, G. T. Motz, N. Svoronos, K. Montone, G. M. Mantia-Smaldone, H. L. Nisenbaum, B. L. Levine, M. Kalos, B. J. Czerniecki, D. A. Torigian, D. J. Powell Jr., R. Mick, L. Smith, G. Coukos, A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: From bench to bedside. Clin. Cancer Res. 19, 4801-4815 (2013).
38. S. A. Cannistra, U. A. Matulonis, R. T. Penson, J. Hambleton, J. Dupont, H. Mackey, J. Douglas, R. A. Burger, D. Armstrong, R. Wenham, W. McGuire, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180-5186 (2007).
39. R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, J. I. Sorosky, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study. J. Clin. Oncol. 25, 5165-5171 (2007).
40. A. A. Garcia, H. Hirte, G. Fleming, D. Yang, D. D. Tsao-Wei, L. Roman, S. Groshen, S. Swenson, F. Markland, D. Gandara, S. Scudder, R. Morgan, H. Chen, H.-J. Lenz, A. M. Oza, Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26, 76-82 (2008).
41. J. J. Wallin, J. C. Bendell, R. Funke, M. Sznol, K. Korski, S. Jones, G. Hernandez, J. Mier, X. He, F. S. Hodi, M. Denker, V. Leveque, M. Cañamero, G. Babitski, H. Koeppen, J. Ziai, N. Sharma, F. Gaire, D. S. Chen, D. Waterkamp, P. S. Hegde, D. F. McDermott, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
42. T. F. Gajewski, H. Schreiber, Y.-X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022 (2013).
43. G. T. Motz, G. Coukos, Deciphering and reversing tumor immune suppression. Immunity 39, 61-73 (2013).
44. E. R. Lutz, A. A. Wu, E. Bigelow, R. Sharma, G. Mo, K. Soares, S. Solt, A. Dorman, A. Wamwea, A. Yager, D. Laheru, C. L. Wolfgang, J. Wang, R. H. Hruban, R. A. Anders, E. M. Jaffee, L. Zheng, Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2, 616-631 (2014).
45. M. Noguchi, F. Moriya, N. Koga, S. Matsueda, T. Sasada, A. Yamada, T. Kakuma, K. Itoh, A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol. Immunother. 65, 151-160 (2016).
46. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772 (2001).
47. C. Iseli, G. Ambrosini, P. Bucher, C. V. Jongeneel, Indexing strategies for rapid searches of short words in genome sequences. PLOS ONE 2, e579 (2007).
48. C. Lundegaard, K. Lamberth, M. Harndahl, S. Buus, O. Lund, M. Nielsen, NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509-W512 (2008).
49. B. M. Carreno, V. Magrini, M. Becker-Hapak, S. Kaabinejadian, J. Hundal, A. A. Petti, A. Ly, W.-R. Lie, W. H. Hildebrand, E. R. Mardis, G. P. Linette, A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
50. + T lymphocytes. Cancer Res. 70, 8368-8377 (2010).
51. + T Cell responsiveness. J. Biol. Chem. 287, 23068-23078 (2012).
52. S. A. Rosenberg, J. C. Yang, N. P. Restifo, Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
53. E. Zsiros, J. Tanyi, K. Balint, L. E. Kandalaft, Immunotherapy for ovarian cancer: Recent advances and perspectives. Curr. Opin. Oncol. 26, 492-500 (2014).
54. B. E. Loveland, A. Zhao, S. White, H. Gan, K. Hamilton, P.-X. Xing, G. A. Pietersz, V. Apostolopoulos, H. Vaughan, V. Karanikas, P. Kyriakou, I. F. C. McKenzie, P. L. R. Mitchell, Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12, 869-877 (2006).
55. V. Möbus, S. Horn, M. Stöck, V. Schirrmacher, Tumor cell vaccination for gynecological tumors. Hybridoma 12, 543-547 (1993).
56. L. E. Kandalaft, C. L. Chiang, J. Tanyi, G. Motz, K. Balint, R. Mick, G. Coukos, A phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J. Transl. Med. 11, 149 (2013).
57. W. Miller, E. W. Myers, Sequence comparison with concave weighting functions. Bull. Math. Biol. 50, 97-120 (1988).
58. J. L. Duke, C. Lind, K. Mackiewicz, D. Ferriola, A. Papazoglou, A. Gasiewski, S. Heron, A. Huynh, L. McLaughlin, M. Rogers, L. Slavich, R. Walker, D. S. Monos, Determining performance characteristics of an NGS-based HLA typing method for clinical applications. HLA 87, 141-152 (2016).
59. M. Nielsen, C. Lundegaard, P. Worning, S. L. Lauemøller, K. Lamberth, S. Buus, S. Brunak, O. Lund, Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007-1017 (2003).
60. M. Nielsen, C. Lundegaard, T. Blicher, K. Lamberth, M. Harndahl, S. Justesen, G. Røder, B. Peters, A. Sette, O. Lund, S. Buus, NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLOS ONE 2, e796 (2007).
61. + T cell responses against viral and tumor antigens using T cells as novel target APC. J. Immunol. Methods 278, 57-66 (2003).
62. S. Viganò, F. Bellutti Enders, I. Miconnet, C. Cellerai, A.-L. Savoye, V. Rozot, M. Perreau, M. Faouzi, K. Ohmiti, M. Cavassini, P.-A. Bart, G. Pantaleo, A. Harari, Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells. PLOS Pathog. 9, e1003423 (2013).
63. A. Harari, V. Rozot, M. Cavassini, F. Bellutti Enders, S. Vigano, G. Tapia, E. Castro, S. Burnet, J. Lange, C. Moog, D. Garin, D. Costagliola, B. Autran, G. Pantaleo, P.-A. Bart, NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur. J. Immunol. 42, 3038-3048 (2012).
64. + T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350-2360 (2011).
65. V. K. Mootha, C. M. Lindgren, K.-F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, M. J. Daly, N. Patterson, J. P. Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J. N. Hirschhorn, D. Altshuler, L. C. Groop, PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
66. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).